financetom
Business
financetom
/
Business
/
Cohen & Steers Preliminary Assets Under Management Rise in May
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cohen & Steers Preliminary Assets Under Management Rise in May
Jun 10, 2024 2:51 PM

05:16 PM EDT, 06/10/2024 (MT Newswires) -- Cohen & Steers ( CNS ) reported late Monday it had preliminary assets under management of about $80.49 billion as of May 31, up from $77.16 billion in the previous month.

The company attributed the increase to market appreciation of $3.57 billion, partially offset by distributions of $150 million and net outflows of $93 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
E3 Lithium Q4 Loss Widens, Lists 2024 Targets
E3 Lithium Q4 Loss Widens, Lists 2024 Targets
Apr 29, 2024
06:58 AM EDT, 04/29/2024 (MT Newswires) -- E3 Lithium ( EEMMF ) over the weekend reported a fourth-quarter net loss of $2.1 million, or $0.03 per share, compared with a loss of $2 million, or $0.03 per share, a year earlier. In 2024, E3 Lithium ( EEMMF ) plans to publish the prefeasibility study results and then to start the...
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance
Apr 29, 2024
06:49 AM EDT, 04/29/2024 (MT Newswires) -- The most-talked-about stocks in the Reddit subforum Wallstreetbets were mostly higher hours before Monday's opening bell. Tesla (TSLA) advanced by 8.4% in premarket hours, reversing a 1.1% decline from the previous session. Tesla is preparing to lay off 693 employees at facilities in Sparks, Nevada, Reuters reported Friday, citing a government filing. ImmunityBio...
US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease
US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease
Apr 29, 2024
April 29 (Reuters) - X4 Pharmaceuticals ( XFOR ) said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in patients 12 years of age and older, sending its shares up 16% before the bell. X4's mavorixafor, which will be sold under the brand name Xolremdi, is the first therapy to get U.S....
Banco Bilbao Vizcaya Argentaria's Q1 Adjusted Earnings, Gross Income Rise
Banco Bilbao Vizcaya Argentaria's Q1 Adjusted Earnings, Gross Income Rise
Apr 29, 2024
06:47 AM EDT, 04/29/2024 (MT Newswires) -- Banco Bilbao Vizcaya Argentaria ( BBVA ) reported Q1 adjusted earnings Monday of 0.37 euro ($0.40) per share, up from 0.30 euro per share a year earlier. Two analysts polled by Capital IQ expected 0.33 euro per share, if comparable. Gross income for the quarter ended March 31 was 8.22 billion euros, up...
Copyright 2023-2026 - www.financetom.com All Rights Reserved